Over Seven Chinese Pharma and MedTech Companies Secure Over RMB 100 Million Each in Funding Within Two Weeks to Advance Drug and Device Development

　　【Pharmaceutical Network Industry DynamicsAccording to incomplete statistics, in the past half month (December 11th - December 22nd), there were over 20 financing and investment events in China's pharmaceuticals and health sector. Among them, more than 7 pharmaceutical enterprises completed billion-yuan financing. The enterprises that received financing are involved in various fields such as new drug development and medical device research and development.
 

On December 18, Novamab announced the completion of a Series B financing round exceeding 100 million RMB. The funds from this round will be used for Phase II clinical research of two inhaled antibody drugs (LQ036, LQ043) independently developed by the company based on its "Inhaled Macromolecule Drug Development Platform." Additionally, the funds will further expand the team and replenish the company's working capital. Novamab focuses on the research and development of inhaled nanobody drugs and has established a comprehensive R&D, CMC, and pilot production system. It has built five innovative technology platforms and, relying on its proprietary technology platforms, developed a series of novel biologics with independent intellectual property rights.
 

On December 18, REETO announced the completion of a multi-million yuan B2 round of financing. The funds will mainly be used for the production, commercialization, and R&D iteration of core products.Biological ProductsThe product matrix covers multiple testing scenarios such as blood, body fluids, tissues, and sputum. Reetoo focuses on the deep integration of artificial intelligence and medical diagnostics. Based on its self-developed next-generation DeepCell engine, it has developed four major analysis systems: intelligent clinical testing, intelligent hematology, intelligent pathology, and intelligent reproductive medicine. It is committed to providing customers with cost-effective and highly efficient AI-based cytological testing solutions. Its product matrix covers multiple testing scenarios such as blood, body fluids, tissues, and sputum, helping to standardize and intelligize the entire testing process.
 

On December 15, NORCHEM announced the completion of a Pre-IPO financing round worth hundreds of millions of RMB. This round of financing will mainly be used for NORCHEM's expansion in the fields of bio-pesticides, bio-fertilizers, and bio-food supplements, as well as the preliminary construction of a synthetic biology industrial base. NORCHEM is a company specializing in steroid drugs.IntermediateAndActive Pharmaceutical IngredientsResearch, production, and sales, with main products covering various corticosteroids, sex hormones, etc.
 

On the same day, REBIRTH BIOTECH announced the completion of a B-round financing of over 100 million yuan. The funds from this round will mainly be used for clinical research and development of core pipelines such as neuro-reparative biologics and articular cartilage repair materials. REBIRTH BIOTECH is a provider of cell biotechnology services with over a decade of deep involvement in the clinical translational application of stem cells. In the second half of 2021, it achieved breakthrough validation in clinical translation, particularly excelling in three key areas: follicle repair, joint repair, and nerve repair.
 

On December 14, Chenchen Pharmaceuticals announced the completion of a 100-million-yuan Series A round of financing. This round of financing will comprehensively accelerate the company's biopharmaceutical R&D outsourcing services, as well as the R&D and production of pharmaceutical raw materials and life science reagents. Chenchen Pharmaceuticals is an innovative company built on solid underlying technologies in chemistry and biology, focusing on improving industry quality. Its core businesses now cover biopharmaceutical R&D outsourcing services, as well as the R&D and production of pharmaceutical raw materials and life science reagents.
 

On December 12, LungHealth Medical announced the completion of a 100-million-yuan C-round financing. This round of financing aims to expand the company's leading position in the field of flexible surgical robots via natural orifices. LungHealth Medical focuses on the research and development of surgical robots. The company has comprehensively laid out plans around next-generation minimally invasive tumor intervention technologies such as natural orifice endoscopic surgical robots and bronchoscopy navigation robots, forming a diverse portfolio of dozens of innovative products.
 

On December 11, Shanghai Huxiang announced the completion of a 100-million-yuan B-round financing. The funds from this round will be used to promote and implement products and solutions such as AI + automation, AI robot scientists, and smart laboratories. Shanghai Huxiang is an artificial intelligence enterprise that focuses on robot and machine vision technology, committed to providing full-process automation systems and solutions for the life science, pharmaceutical, clinical diagnosis, and analytical testing industries.
 

Disclaimer: In no case shall the information or opinions expressed in this article constitute investment advice to any person.